IL137566A0 - N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors - Google Patents

N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Info

Publication number: IL137566A0
Authority: IL; Israel
Prior art keywords: aryl; alkyl; heteroarylamides; sulfinyl; sulfonyl
Prior art date: 1998-02-19

Application number

IL13756698A

Original Assignee

American Cyanamid Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-19

Filing date

1998-08-26

Publication date

2001-07-24

1998-08-26 Application filed by American Cyanamid Co filed Critical American Cyanamid Co

2001-07-24 Publication of IL137566A0 publication Critical patent/IL137566A0/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/14—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Emergency Medicine (AREA)

IL13756698A 1998-02-19 1998-08-26 N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors IL137566A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2637298A	1998-02-19	1998-02-19
PCT/US1998/017633 WO1999042436A1 (en)	1998-02-19	1998-08-26	N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Publications (1)

Publication Number	Publication Date
IL137566A0 true IL137566A0 (en)	2001-07-24

Family

ID=21831431

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13756698A IL137566A0 (en)	1998-02-19	1998-08-26	N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors

Country Status (21)

Country	Link
EP (1)	EP1054858A1 (en)
JP (1)	JP2002503717A (en)
KR (1)	KR20010041089A (en)
CN (1)	CN1213021C (en)
AU (1)	AU757719B2 (en)
BG (1)	BG104782A (en)
BR (1)	BR9815781A (en)
CA (1)	CA2320469A1 (en)
EA (1)	EA003283B1 (en)
EE (1)	EE200000471A (en)
GE (1)	GEP20022797B (en)
HR (1)	HRP20000543A2 (en)
HU (1)	HUP0101837A3 (en)
ID (1)	ID25639A (en)
IL (1)	IL137566A0 (en)
NO (1)	NO20004093L (en)
NZ (1)	NZ506184A (en)
PL (1)	PL342548A1 (en)
SK (1)	SK12332000A3 (en)
TR (1)	TR200002423T2 (en)
WO (1)	WO1999042436A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6750228B1 (en) *	1997-11-14	2004-06-15	Pharmacia Corporation	Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en)	1997-11-14	2001-11-08	Thomas E Barta	Aromatic sulfone hydroxamic acid metalloprotease inhibitor
PL341379A1 (en)	1997-11-14	2001-04-09	Searle & Co	Aromatic sulphone substituted hydroxamic acid as inhibitor of metalloprotease
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
AR035312A1 (en) *	1999-01-27	2004-05-12	Wyeth Corp	HYDROXAMIC ACID COMPOUNDS CONTAINING ALQUINYL AS MATRIX / TACE METALOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITION THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
BR0007784A (en) *	1999-01-27	2002-02-05	American Cyanamid Co	Compound, method for inhibiting pathological changes mediated by the enzyme that converts tnf-alpha (tace) into a mammal, pharmaceutical composition, and, process for preparing a compound
US6800646B1 (en)	1999-02-08	2004-10-05	Pharmacia Corporation	Sulfamato hydroxamic acid metalloprotease inhibitor
GEP20043238B (en)	1999-02-08	2004-05-25	Searle & Co	Sulfamato Hydroxamic Acid Metalloprotease Inhibitor, its Use in Preparation of Pharmaceutical Composition for Treatment of Conditions Associated with Pathological Matrix Metalloprotease Activity
AU2001233034A1 (en) *	2000-01-27	2001-08-07	American Cyanamid Company	Method for preparing alpha-sulfonyl hydroxamic acid derivatives
UY26664A1 (en) *	2000-04-14	2001-11-30	Abbott Lab	HYDRAZIDES AND ALCOXIAMIDAS INHIBITORS OF ANGIOGENESIS.
US20020002152A1 (en)	2000-04-14	2002-01-03	Craig Richard A.	Hydrazide and alkoxyamide angiogenesis inhibitors
US6683093B2 (en)	2000-05-12	2004-01-27	Pharmacia Corporation	Aromatic sulfone hydroxamic acids and their use as protease inhibitors
AP2003002908A0 (en)	2001-05-11	2003-12-31	Pharmacia Corp	Aromatic sulfone hydroxamates and their use as protease inhibitors
PE20030701A1 (en)	2001-12-20	2003-08-21	Schering Corp	COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
EP1501827A2 (en)	2002-04-25	2005-02-02	Pharmacia Corporation	Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors
JP2006502980A (en) *	2002-06-25	2006-01-26	ファルマシア・コーポレーション	Arylsulfonylhydroxamic acid and amide derivatives and their use as protease inhibitors
TW200418825A (en)	2002-12-16	2004-10-01	Hoffmann La Roche	Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
JP2008518923A (en) *	2004-11-01	2008-06-05	ヌアダ，リミテッド・ライアビリティ・カンパニー	Compounds and methods of use thereof
FR2917427B1 (en) *	2007-06-18	2009-08-21	Galderma Res & Dev	TACE INHIBITORS IN ACNE TREATMENT
FR2947268B1 (en)	2009-06-30	2011-08-26	Galderma Res & Dev	NOVEL BENZENE-SULFONAMIDE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND THEIR USE IN MEDICINE AND COSMETICS
EP2877446B9 (en) *	2012-07-18	2017-01-25	Proyecto de Biomedicina Cima, S.L.	New antifibrinolytic compounds
WO2016032120A1 (en) *	2014-08-27	2016-03-03	씨제이헬스케어 주식회사	Novel amino-phenyl-sulfonyl-acetate derivative and use thereof
KR101641023B1 (en) *	2014-08-27	2016-07-20	씨제이헬스케어 주식회사	Novel amino-phenyl-sulfonyl-acetate derivatives and use thereof
CN107188837B (en) *	2017-06-06	2019-05-28	温州大学	A kind of synthetic method of α-acyl group high allyl thio-ether type compounds
US20210393632A1 (en)	2018-10-04	2021-12-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Egfr inhibitors for treating keratodermas

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8827305D0 (en) *	1988-11-23	1988-12-29	British Bio Technology	Compounds
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) *	1993-01-06	1996-04-09	Ciba-Geigy Corporation	Arylsufonamido-substituted hydroxamic acids
DE69529100T2 (en) *	1994-01-22	2003-07-17	British Biotech Pharmaceuticals Ltd., Cowley	metalloproteinase
WO1995035275A1 (en) *	1994-06-22	1995-12-28	British Biotech Pharmaceuticals Limited	Metalloproteinase inhibitors
EP0973512B1 (en) *	1997-02-27	2004-04-07	Wyeth Holdings Corporation	N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
JPH11199512A (en) *	1997-10-24	1999-07-27	Pfizer Prod Inc	Use of mmp-13 selective inhibitor for the treatment of arthrosis deformans and other mmp-mediated disease
PL341379A1 (en) *	1997-11-14	2001-04-09	Searle & Co	Aromatic sulphone substituted hydroxamic acid as inhibitor of metalloprotease

1998
- 1998-08-26 IL IL13756698A patent/IL137566A0/en unknown
- 1998-08-26 EA EA200000849A patent/EA003283B1/en not_active IP Right Cessation
- 1998-08-26 KR KR1020007009128A patent/KR20010041089A/en not_active Withdrawn
- 1998-08-26 PL PL98342548A patent/PL342548A1/en unknown
- 1998-08-26 HU HU0101837A patent/HUP0101837A3/en unknown
- 1998-08-26 SK SK1233-2000A patent/SK12332000A3/en unknown
- 1998-08-26 TR TR2000/02423T patent/TR200002423T2/en unknown
- 1998-08-26 NZ NZ506184A patent/NZ506184A/en unknown
- 1998-08-26 EE EEP200000471A patent/EE200000471A/en unknown
- 1998-08-26 EP EP98943392A patent/EP1054858A1/en not_active Withdrawn
- 1998-08-26 CA CA002320469A patent/CA2320469A1/en not_active Abandoned
- 1998-08-26 ID IDW20001549A patent/ID25639A/en unknown
- 1998-08-26 CN CNB988139669A patent/CN1213021C/en not_active Expired - Fee Related
- 1998-08-26 JP JP2000532389A patent/JP2002503717A/en active Pending
- 1998-08-26 HR HR20000543A patent/HRP20000543A2/en not_active Application Discontinuation
- 1998-08-26 BR BR9815781-7A patent/BR9815781A/en not_active Application Discontinuation
- 1998-08-26 GE GEAP19985554A patent/GEP20022797B/en unknown
- 1998-08-26 WO PCT/US1998/017633 patent/WO1999042436A1/en not_active Application Discontinuation
- 1998-08-26 AU AU91201/98A patent/AU757719B2/en not_active Ceased
2000
- 2000-08-16 NO NO20004093A patent/NO20004093L/en unknown
- 2000-09-19 BG BG104782A patent/BG104782A/en unknown

Also Published As

Publication number	Publication date
CA2320469A1 (en)	1999-08-26
SK12332000A3 (en)	2001-02-12
NO20004093L (en)	2000-10-03
CN1213021C (en)	2005-08-03
KR20010041089A (en)	2001-05-15
NO20004093D0 (en)	2000-08-16
JP2002503717A (en)	2002-02-05
BR9815781A (en)	2000-11-07
PL342548A1 (en)	2001-06-18
EA003283B1 (en)	2003-04-24
NZ506184A (en)	2003-05-30
HUP0101837A2 (en)	2001-10-28
CN1291183A (en)	2001-04-11
WO1999042436A1 (en)	1999-08-26
ID25639A (en)	2000-10-19
HRP20000543A2 (en)	2001-08-31
GEP20022797B (en)	2002-09-25
EE200000471A (en)	2002-02-15
HUP0101837A3 (en)	2001-11-28
AU757719B2 (en)	2003-03-06
BG104782A (en)	2001-08-31
TR200002423T2 (en)	2001-01-22
AU9120198A (en)	1999-09-06
EP1054858A1 (en)	2000-11-29
EA200000849A1 (en)	2001-04-23

Publication	Publication Date	Title
IL131257A0 (en)	2001-01-28	N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl sulfinyl or sulfonyl)-3-substituted alkyl aryl or heteroarylamides as matrix metalloproteinase inhibitors
IL137566A0 (en)	2001-07-24	N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
DK1114032T3 (en)	2004-08-16	4-Amino-substituted-2-substituted-1,2,3,4-tetrahydroquinolines as CETB inhibitors
DK1114033T3 (en)	2004-12-20	4-Carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors
AU2001259589A1 (en)	2001-11-20	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
NO20011350L (en)	2001-05-09	4-Carboxyamino Substituted 1,2,3,4-Tetrahydroquinolines as CETP Inhibitors
EE200000720A (en)	2002-04-15	Novel 3-aryl-2-hydroxypropanoic acid derivative (I)
DK2253620T3 (en)	2014-03-31	SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN-TYROSINKINASE INHIBITORS
DE60215848D1 (en)	2006-12-14	1,2,4-thiadiazole compounds as melanocortinreceptor modulators
NO20022558D0 (en)	2002-05-29	4-Carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as CETP inhibitor
NO20016319D0 (en)	2001-12-21	VLA-4 inhibitor compounds
AU2594799A (en)	1999-08-30	Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
AU6059999A (en)	2000-04-17	2-substituted heterocyclic sulfonamides
DE60009260D1 (en)	2004-04-29	THIOPYRANDERIVATE AS MMP INHIBITORS
HUP0101465A3 (en)	2002-11-28	Process for alkylating hindered sulfonamides effective as matrix metalloproteinase inhibitors
SI0973512T1 (en)	2004-08-31	N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
HK1029113A (en)	2001-03-23	N-hydroxy-2-(alkyl, aryl, of heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
ZA995455B (en)	2001-02-26	N-hydroxy-2(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors.
HK1024904A (en)	2000-10-27	N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
AU3062200A (en)	2000-08-29	Sulphur removal
IT1313141B1 (en)	2002-06-17	CLOSURE FOR NECKLACE